ArticlePLOS global public health2025
Trends in statin prescription among osteoporosis patients: A retrospective cohort study using UK primary care data.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin prescribing patterns in osteoporosis patients remain uncharacterized despite cardiovascular disease being a leading cause of mortality in this population. This study examined temporal trends and demographic variations in statin prescription rates among osteoporosis patients in the UK. This research is a retrospective cohort study utilizing the IQVIA Medical Research Data (IMRD) spanning 2005-2019. Patients' diagnosis of osteoporosis and corresponding statin prescription data were extracted. Prevalence and incidence of statin prescription were calculated, followed by age-stratified and gender-stratified trends analysis using joinpoint regression to calculate the average percent change (APC), annual average percent change (AAPC), and identify significant temporal shifts. Among 157,483 identified osteoporosis patients, statin prescribing trends demonstrated significant reductions in both prescription prevalence (AAPC: -1.03%, p = 0.005) and incidence rate (AAPC:-1.82%, p < 0.001). Gender-based analysis revealed higher prescription rates and more pronounced declines in male patients (prevalence AAPC:2.7% vs female -0.8%), resulting in prescription rate convergence by study end. Age stratified findings showed the 70-79 years age group maintained the highest initial prevalence but experienced the steepest declines. A notable breakpoint occurred in 2018 within the 50-59 age cohort, which may be a result of stricter ACC/AHA cholesterol guidelines requiring enhanced risk-based criteria for primary and secondary prevention. The prescription peaks in 2006 and 2014 likely coincided with NICE guideline modifications. Despite these guideline expansions encouraging broader statin use, sensitivity analysis of cumulative defined daily dose revealed persistently high discontinuation rates in osteoporosis patients. These patterns indicate substantial gaps in cardiovascular protection for this vulnerable population. Declining statin prescription trends among osteoporosis patients, particularly among elderly males, appear to reflect an evolution in clinical practices toward risk-benefit assessment. These findings highlight the need for treatment guideline advancement that addresses both appropriate statin initiation and strategies to improve long-term adherence in patients with multimorbidity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.